Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 2
A Phase 2 Randomized Trial of Sacituzumab Tirumotecan (MK2870) Alone and in Combination With Pembrolizumab in Ovarian Clear Cell Carcinoma Previously Exposed to Immunotherapy
This is a phase II randomized study of Sacituzumab tirumotecan, an intravenous antibody-drug conjugate (ADC) that targets Trop-1, administered alone or in comb…
Ovarian Clear Cell CarcinomaMetastatic Ovarian CancerRecurrent Ovarian Clear Cell Adenocarcinoma
Estimated
~$10 – $6,250
Tufts Medical CenterNCT07718854
Phase 1
A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitum…
Advanced Solid TumorDiffuse Large B Cell LymphomaLymphoma, T-Cell+5 more
Estimated
~$10 – $8,750
Novartis PharmaceuticalsNCT04104776
Phase 3
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemothera…
Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CancerFallopian Tube Cancer+4 more
Estimated
~$10 – $8,750
Genelux CorporationNCT05281471
Phase 1
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma
Ovarian Clear Cell Carcinoma
Estimated
~$10 – $6,250
M.D. Anderson Cancer CenterNCT06065462